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ABSTRACT 
Quercetin, a dietary flavonoid, has been reported to possess anti-platelet activity. However, 
its extensive metabolism following ingestion has resulted in difficulty elucidating precise 
mechanisms of action. In this study, we aimed to characterise the anti-platelet mechanisms 
of two methylated metabolites of quercetin - isorhamnetin and tamarixetin - and explore 
potential interactions with aspirin. Isorhamnetin and tamarixetin inhibited human platelet 
aggregation, and suppressed activatory processes including granule secretion, integrin αIIbβ3 
function, calcium mobilisation, and Syk/LAT phosphorylation downstream of GPVI with 
similar potency to quercetin. All three flavonoids attenuated thrombus formation in an in 
vitro microfluidic model, and isoquercetin, a 3-O-glucoside of quercetin, inhibited thrombosis 
in a murine laser injury model. Isorhamnetin, tamarixetin and quercetin enhanced the anti-
platelet effects of aspirin more-than-additively in a plate-based aggregometry assay, reducing 
aspirin IC50 values by an order of magnitude, with this synergy maintained in a whole blood 
test of platelet function. Our data provide mechanistic evidence for the anti-platelet activity 
of two quercetin metabolites, isorhamnetin and tamarixetin, and suggest a potential anti-
thrombotic role for these flavonoids. In combination with their interactions with aspirin, this 
may represent a novel avenue of investigation for the development of new anti-thrombotic 
strategies and management of current therapies. 
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INTRODUCTION 
Platelets are small, anucleate cells critical to the haemostatic process.1 Upon vessel injury, 
platelets are activated via interaction of cell surface receptors with collagen and subsequent 
activation via soluble agonists such as ADP (adenosine diphosphate), thromboxane A2 (TXA2) 
and thrombin, leading to a cascade of intracellular events including calcium mobilization, 
granule secretion and integrin activation.2 This leads to the formation of platelet aggregates, 
development of thrombi, and the cessation of bleeding. The activation of this cascade under 
pathophysiological conditions can, however, result in the occlusion of vessels through 
thrombus formation, or thrombosis, leading to events such as stroke or myocardial 
infarction.3 The pharmacological targeting of platelet activation pathways with anti-platelet 
medications has proven very successful; medications such as aspirin, the most widely used 
agent worldwide are, however, associated with a lack of effect in some patients, and are 
associated with adverse events such as bleeding, raising a priority for the development of 
more efficacious and safer alternative therapeutic approaches.4,5  
The link between diet and cardiovascular disease (CVD) is well established, with many cohort 
studies demonstrating the beneficial effects of fruit and vegetable intake, and specifically 
flavonoid intake, on cardiovascular health.6,7 Quercetin is a commonly consumed flavonoid 
found in foods such as apples, onions and red wine, and has demonstrated beneficial 
properties in numerous studies reporting anti-cancer, anti-microbial and anti-viral effects.8,9 
In addition to this, quercetin intake has been implicated in reduced CVD risk in both 
interventional and observational studies, with intake linked to a reduction in plasma low-
density lipoprotein (LDL), reduced systolic and diastolic blood pressure, and reduced risk of 
ischemic heart disease.10,11 Quercetin is also reported to possess anti-platelet effects, with an 
inhibition of platelet aggregation upon in vitro addition as well as ex vivo post 
supplementation. 12,13 These anti-platelet effects have not, however, been fully characterised. 
Upon consumption, quercetin is metabolised extensively in the small intestine and liver, 
yielding conjugated metabolites; the anti-platelet effects of these in vivo ‘effectors’ has 
received considerably less attention.14 Further to this, the potential for interactions between 
quercetin, its metabolites, and currently used anti-platelet medications such as aspirin is an 
important avenue of investigation; interactions between these substances must be explored 
in order to understand the nature of anti-platelet efficacy upon their simultaneous presence 
in plasma. 
In this study, we investigate the anti-platelet effects of isorhamnetin and tamarixetin, two 
methylated metabolites of quercetin, which were found to inhibit platelet function through 
effects on granule secretion, integrin activation, calcium mobilisation and phosphorylation of 
key signalling proteins downstream of glycoprotein VI (GPVI), resulting in antithrombotic 
effects in vitro. In addition, anti-thrombotic effects of isoquercetin were displayed in a murine 
model of thrombosis, and we provide compelling evidence that quercetin and its metabolites 
synergise with aspirin in the inhibition of platelet function. 
 
MATERIALS AND METHODS 
Materials 
Tamarixetin, isorhamnetin and quercetin-3-glucuronide were from Extrasynthese (Lyon, 
France). Isoquercetin was from Quercegen Pharmaceuticals LLC (Massachusetts, USA). 
Fibrillar type I collagen was from Takeda (Linz, Austria), and cross-linked collagen-related 
peptide (CRP-XL) was provided by Professor Richard Farndale (University of Cambridge, UK). 
Phycoerythrin (PE)/Cy5 anti-human CD62P antibody was from BD Biosciences (New Jersey, 
USA), and fluorescein isothiocyanate (FITC) anti-human fibrinogen antibody was from Dako 
(Glostrup, Denmark). Anti-LAT (Linker for Activation of T cells) phosphotyrosine 200 and anti-
Syk (Spleen tyrosine kinase) phosphotyrosine 525+526 antibodies were from Abcam 
(Cambridge, UK). Alexa-Fluor 488 donkey anti-goat, Alexa-Fluor 647 donkey anti-rabbit 
conjugated antibody and Fura-2 AM were from Life Technologies (Paisley, UK). Anti- 3 
integrin (N-20) goat polyclonal antibody was from Santa-Cruz Biotechnology (Heidelberg, 
Germany). DyLight 649 conjugated anti-GPIbα antibody was from EMFRET analytics 
(Würzburg, Germany). CHRONO-LUME ATP detection kit was from Chronolog (Pennsylvania, 
USA) and Alexa-Fluor 488 conjugated phalloidin was from Thermo-Fisher Scientific 
(Massachusetts, USA). Precision Plus Protein dual colour standard, 10X Tris/Glycine/SDS 
buffer, Immun-Blot PVDF membrane and 4-20% Mini-PROTEAN TGX (Tris-Glycine eXtended) 
precast protein gels were from Bio-Rad (Hertfordshire, UK). 96-well flat bottom plates were 
from Greiner Bio-One (Stonehouse, UK). Vena8 Fluoro+ biochips were from Cellix Ltd (Dublin, 
Ireland). Platelet function analyser (PFA)-100 cartridges were from Sysmex (Milton Keynes, 
UK). All other reagents were from Sigma Aldrich (Gillingham, UK).  
 
Methods 
Light transmission measured via aggregometry, P-Selectin exposure and fibrinogen binding 
measured via flow cytometry, dense granule secretion measured via lumi-aggregometry, 
adhesion and spreading on fibrinogen, clot retraction and calcium mobilisation were 
performed using standard techniques as described previously.15-19 Immunoblotting was 
performed using standard protocols as described previously, with proteins of interest 
detected using specific antibodies raised against them and fluorophore-conjugated secondary 
antibodies.16 A Typhoon FLA 9500 scanner (GE Healthcare) was used to visualise proteins, and 
protein levels were normalised to loading controls.  
 
Platelet preparation 
Washed platelet preparation was performed via differential centrifugation as described 
previously.16 Platelets were resuspended to the appropriate density in modified Tyrodes- 
HEPES buffer (134mM NaCl, 2.9mM KCl, 12mM NaHCO3, 0.34mM Na2HPO4, 1mM MgCl2, 
20mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid, 5mM glucose, pH7.3) and rested 
at 30oC for 30 minutes before use. 
 
Plate-based aggregometry 
Plate-based aggregometry was performed as previously described by Chan et al.20 Washed 
platelets (2x108 cells/mL) or platelet rich plasma (PRP) were loaded into 96-well plates and 
incubated with vehicle control or flavonoids (5 minutes in washed platelets, 30 minutes in 
PRP), aspirin (30 minutes), or both, prior to agonist addition, after which plates were shaken 
at 1200rpm for 5 minutes at 37oC using a BioShake iQ (Quantifoil Instruments, Jena, 
Germany). Transmission of light (405nm) was measured using a NOVOstar plate reader (BMG 
Labtech, Aylesbury, UK), and values converted to percentage aggregation using unstimulated 
and agonist-stimulated samples to represent 0% and 100%, respectively.  
 
In vitro thrombus formation 
Citrated human whole blood was incubated with 5 M DiOC6 for 1 hour at 30oC, and Vena8 
BioChip microfluidic channels were coated for one hour with type I collagen at room 
temperature; excess collagen was washed through the channels with modified Tyrodes- 
HEPES buffer. Whole blood was incubated with flavonoids or vehicle control for 10 minutes 
at 30oC prior to perfusion through microfluidic channels at a shear rate of 20dyn/cm2. Using 
a Nikon A1-R confocal microscope, fluorescence was excited at 488nm, and emission detected 
at 500-520nm; the channel was observed under a 20X objective and images captured every 
second for 600s. Mean fluorescence intensity was subsequently calculated with NIS Elements 
software (Nikon, Tokyo, Japan). 
 
Thrombus formation in vivo 
C57/BL6 mice were dosed with isoquercetin twice per day by oral gavage; once in the morning 
and once in the afternoon. This was performed for 48 hours prior to commencement of the 
experiment, with one final dose the morning of the experiment. Mice were anaesthetised by 
intraperitoneal ketamine (125mg/kg), xylazine (12.5mg/kg) and atropine (0.25mg/kg) 
injection, and maintained with pentobarbital (5mg/kg) as required, through a carotid artery 
cannula. The cremaster muscle of the testicle was affixed over a glass slide, and platelets were 
labelled with DyLight 649 anti-GPIb antibody (0.2 g/g mouse weight). Arteriole walls were 
injured using a Micropoint ablation laser unit (Andor Technology PLC, Belfast, Northern 
Ireland), with thrombus formation observed using an Olympus BX61W1 microscope (Olympus 
Corporation, Tokyo, Japan). Images were captured prior to and after injury using a 
Hamamatsu digital camera C9300 charged-couple device camera (Hamamatsu Photonics UK 
Ltd, Hertfordshire, UK) in 640x480 format. Images were analysed using Slidebook 6 software 
(Intelligent Imaging Innovations, Colorado, USA). Experiments in mice were performed under 
a UK Home Office licence after approval from the University of Reading Local Ethical Review 
Panel. 
 
Platelet Function Analyser 100 (PFA-100) 
Citrated human whole blood was incubated with flavonoids, aspirin or vehicle control for 30 
minutes at 30oC, after which 800 L was pipetted into the reservoir of PFA-100 test cartridges. 
Cartridges were loaded into the PFA-100 analyser carousel and samples were run in an 
automated process, drawing blood through an aperture in a collagen/ADP or 
collagen/epinephrine-coated membrane at a shear rate of 5000-6000s-1, and outputting a 
closure time upon occlusion. 
 
Statistical analysis 
Statistical analyses were performed using Prism Version 7 (Graphpad, California, USA). Aspirin 
plus flavonoid aggregometry data were analysed by 2-way ANOVA (analysis of variance) with 
post-hoc Dunnett’s multiple comparisons test. In vitro thrombus formation and protein 
phosphorylation data were analysed by 2-way ANOVA with post-hoc Bonferroni multiple 
comparison test. In vivo thrombus formation data were analysed by unpaired ttests, and 
synergistic (more-than-additive) effects were established using paired t-tests. All other data 
were analysed by one-way ANOVA with post-hoc Dunnett’s multiple comparison test. Data 
are presented as mean ± SEM (standard error of mean), with P ≤0.05 considered statistically 
significant. 
 
RESULTS 
Tamarixetin and isorhamnetin inhibit platelet aggregation evoked by collagen 
Collagen is exposed on the subendothelium upon vessel injury, and is a key activatory 
substance in the haemostatic response.21 We therefore investigated whether key metabolic 
changes to quercetin (i.e. methylation) affected the ability to inhibit collagen-stimulated 
washed platelet aggregation. Reported physiological plasma concentrations vary widely 
according to supplementation/dietary method, dose, and the form of quercetin 
administered; a range between 0-10μM was used here (and throughout) to represent a 
feasible physiological concentration range (with the upper level of 10μM representing a high, 
yet achievable plasma concentration of total quercetin).12,22,23 Isorhamnetin, the 3’ 
methylated metabolite of quercetin, concentration-dependently inhibited collagen-
stimulated platelet aggregation with an IC50 (half maximal Inhibitory Concentration) value of 
4.76 ± 0.99µM (Figure 1A,B). In contrast to this, tamarixetin, the 4’ methylated metabolite of 
quercetin, displayed reduced potency, inhibiting platelet aggregation fully at concentrations 
above 20µM, with an IC50 value of 7.21 ± 0.33µM (Figure 1C,D). Quercetin inhibited 
aggregation at concentrations >5µM, with an IC50 of 5.72 ± 0.51µM (Figure 1E,F). The 
structures of the flavonoids investigated are shown in Suppl. Figure 1 (available online). These 
results indicate methylation at the 3’ position (isorhamnetin) confers a moderately higher 
inhibitory potency compared to methylation at the 4’ position (tamarixetin) or possession of 
a B ring catechol moiety (quercetin). This was confirmed upon stimulation with multiple 
collagen concentrations, with isorhamnetin displaying the most potent inhibitory profile 
(Suppl. Figure 2). In addition to this, isorhamnetin, tamarixetin and quercetin inhibited 
aggregation evoked by ADP, U46619 (a stable thromboxane A2 analog) and thrombin, 
providing evidence for GPCR (G-Protein coupled receptor)-mediated pathway inhibition by 
the methylated metabolites of quercetin (Suppl. Figure 3). 
 
Platelet granule secretion is inhibited by the methylated metabolites of 
quercetin 
The secretion of platelet granules is a key process driving the positive feedback cycle of 
activation; dense granules are rich in small molecules such as adenosine triphosphate (ATP), 
ADP and serotonin, and α-granules contain proteins such as fibronectin, P-Selectin and von 
Willebrand Factor.24 In order to elucidate whether the anti-aggregatory effects of tamarixetin 
and isorhamnetin were due to an upstream effect on dense granule secretion, collagen-
stimulated (5 g/mL) secretion of ATP from washed platelets was investigated. Isorhamnetin, 
tamarixetin and quercetin inhibited dense granule secretion; a concentration dependent 
reduction in ATP secretion was observed with isorhamnetin between 2.5-10µM, with 
76%±4.4 inhibition at the highest concentration tested (10 M)(Figure 2A,B). Secretion was 
reduced significantly by tamarixetin at concentrations between 5-10µM (Figure 2E,F). 
Quercetin effected dense granule secretion similarly to tamarixetin, with a maximal inhibition 
of 70%±3.9 at 10µM (Figure 2I,J). The ability of tamarixetin and isorhamnetin to attenuate the 
exposure of P-Selectin upon stimulation with collagen-related peptide (1µg/mL CRP-XL, cross-
linked: a GPVI-selective ligand that is compatible with flow cytometry analysis) was also 
investigated, as a marker of α-granule secretion. Isorhamnetin inhibited significantly this 
process at all concentrations tested, with a 39±4.9% reduction in P-Selectin exposure upon 
treatment with a low flavonoid concentration of 0.5µM (IC50 2.57 ± 1.91µM)(Figure 2C,D). 
Tamarixetin inhibited comparably, with a significant effect at 1 M plus, and an IC50 of 2.71 ± 
0.27µM (Figure 2G,H). Quercetin also attenuated P-Selectin exposure as low as 0.5µM 
(14%±2.7 inhibition), a readily achievable physiological concentration, with an IC50 of 2.51 ± 
0.23µM (Figure 2K,L). Overall, these data suggest one of the key mechanisms through which 
isorhamnetin and tamarixetin inhibit aggregation is through an early effect on granule 
secretion. 
Integrin αIIbβ3 signalling is modulated by the quercetin metabolites tamarixetin 
and isorhamnetin 
Upon activation, signals from within the platelet function to upregulate the affinity of integrin 
αIIbβ3 into an ‘open’ state (via ‘inside-out signalling’), to which fibrinogen binds, ultimately 
leading to aggregation.25 As it is known that quercetin functions as a broad spectrum inhibitor 
of protein kinases, it was hypothesised that this integrin affinity regulation may be modulated 
by the flavonoids. This was measured by investigating CRP-XL (1µg/mL) stimulated fibrinogen 
binding to ‘open’ integrin αIIbβ3. All three flavonoids tested inhibited significantly the binding 
of fibrinogen; upon treatment with isorhamnetin, a significantly increased level of inhibition 
at lower flavonoid concentrations (1µM) compared to quercetin and tamarixetin was 
observed (p<0.05), with 34%±3.5 inhibition at 1µM (Figure 3A). Isorhamnetin reduced 
fibrinogen binding between 1-10 M, as did tamarixetin, with IC50 values of 6.27 ± 2.81µM 
and 5.29 ± 1.58µM, respectively (Figure 3A,B). Quercetin attenuated fibrinogen binding at all 
concentrations tested, with >25% inhibition at 0.5µM. Indeed, over 95% inhibition was 
achieved upon treatment with 7.5µM, with an IC50 of 3.13 ± 0.46µM (Figure 3C). Upon ligand 
binding to integrin αIIbβ3, receptor clustering causes ‘outside-in’ signalling events that result 
in platelet spreading, platelet thrombus contraction, and ultimately downstream clot 
retraction.26 In order to determine whether outside-in signalling may be affected by the 
methylated metabolites, platelet spreading on fibrinogen was investigated. All flavonoids 
tested inhibited significantly platelet adhesion on fibrinogen at 1, 2.5 and 5μM 
(representative images shown in Figure 3D). The spreading of platelets on fibrinogen was also 
inhibited upon treatment with flavonoid concentrations as low as 1µM, with fewer platelets 
able to fully form lamellipodia, instead progressing only to the adhered or filopodia-extending 
stages (Figure 3E-G). Consistent with other functional data in washed platelets, isorhamnetin 
proved significantly more potent (p<0.05) than quercetin and tamarixetin at lower 
concentrations (1μM).  
Clot retraction was also investigated as a measure of outside-in signalling, utilising platelet 
rich plasma and a thrombin-stimulated clot. Retraction was inhibited by isorhamnetin and 
tamarixetin between 2.5-10µM, and by quercetin between 5-10µM. Indeed, Figure 3 (H-J) 
shows that, upon 10µM treatment, retraction of clots was reduced substantially after 2 hours 
(when vehicle-treated clots had fully retracted). Tamarixetin had the largest effect, with a 
6.5X larger clot weight at 2h compared to vehicle control; this suggests that, in the presence 
of plasma proteins, a 4’ methyl group confers increased inhibitory potency. This is supported 
by the observation that tamarixetin inhibits significantly platelet aggregation in PRP at 
concentrations of 10µM and higher, with quercetin and isorhamnetin inhibiting significantly 
25µM (the higher concentrations required here may be explained by stirring conditions and 
use of collagen (5µg/mL) as agonist)(Suppl. Figure 4). These data display inhibitory effects of 
quercetin and its methylated metabolites at physiologically achievable concentrations in the 
presence of plasma proteins, and suggests a role for these flavonoids in integrin αIIbβ3 
outside-in signalling inhibition.  
 
Isorhamnetin potently inhibits CRP-XL stimulated cytosolic calcium elevation 
The mobilisation of calcium from intracellular platelet stores and the entry of calcium into the 
cell is crucial for platelet activation, driving granule secretion and integrin αIIbβ3 activation.27 
As these downstream processes were inhibited, it was investigated whether an upstream 
effect on calcium mobilization was associated with diminished platelet reponses. Cytosolic 
calcium elevation stimulated by CRP-XL (1µg/mL) was inhibited significantly by isorhamnetin 
between 1-10µM, with 34%±8.2 inhibition at 1µM, and a maximal effect of 87%±3.7 (Figure 
4A,B). Tamarixetin attenuated calcium elevation less potently, with a significant reduction 
between 5-10µM (Figure 4C,D). Quercetin also inhibited at all concentrations tested, with a 
reduced maximum effect of 61%±6.8 compared to isorhamnetin (Figure 4E,F). 
 
Early signalling events downstream of GPVI are inhibited by isorhamnetin and 
tamarixetin 
Glycoprotein VI (GPVI) is a transmembrane collagen receptor associated with an FcRγ-chain 
dimer. Upon ligand binding, strong platelet activation occurs, driven largely by protein kinase 
signalling. As the methylated metabolites of quercetin inhibited platelet activation via this 
pathway, their ability to inhibit phosphorylation of signalling proteins downstream of GPVI, 
namely Spleen tyrosine kinase (Syk) and Linker for Activation of T Cells (LAT), was investigated. 
Upon stimulation with CRP-XL (1µg/mL), Syk and LAT phosphorylation peaked at 40 seconds, 
decreasing after this time up to 300s (representative blots are shown in Figure 4G/H). Upon 
treatment with isorhamnetin (7.5µM, chosen as an intermediate concentration used in 
aggregometry assays), peak Syk phosphorylation (the highest level of phosphorylation across 
the time-course) was delayed to 90s, and was inhibited by 51%±16.2 compared to control 
(Figure 4I). Tamarixetin delayed peak Syk phosphorylation to 90s, with no significant 
difference in peak levels (Figure 4J). Quercetin treatment delayed peak Syk phosphorylation 
to 60s, and, like isorhamnetin, inhibited it significantly (a 49%±12 reduction, Figure 4K). 
Isorhamnetin potently inhibited the CRP-XL stimulated phosphorylation of LAT, with no real 
peak observed, and a significant reduction compared to vehicle control between 25-40s 
(Figure 4L). Tamarixetin again delayed peak phosphorylation to 90 seconds, with a 90% 
reduction compared to vehicle control between 30 and 40 seconds (Figure 4M). Quercetin 
treatment resulted in a delay in peak phosphorylation to 60s; between 25-40s, significant 
inhibition was observed, up to 90% (Figure 4N). There was, however, no effect on peak 
phosphorylation levels by any flavonoid, possibly due to high inter-individual variance. These 
data suggest that like quercetin, tamarixetin and isorhamnetin both delay and impair 
phosphorylation of some of the immediate effectors of the GPVI pathway, likely leading to 
downstream signalling alteration and the observed functional inhibition. 
 
Isorhamnetin and tamarixetin inhibit thrombus formation in vitro 
Due to the potent inhibitory effects of isorhamnetin and tamarixetin on platelet function, it 
was hypothesised that these metabolites of quercetin may demonstrate anti-thrombotic 
properties. The effects of these flavonoids on thrombus formation were therefore tested in 
vitro under physiological arterial flow conditions. Vehicle-treated blood perfused over 
collagen formed thrombi normally, increasing in size as platelets accumulated over the 10- 
minute assay period. Upon flavonoid treatment, thrombus formation (measured as an 
increase in fluorescence intensity) was inhibited from early time points, reaching significance 
from 140 seconds onwards upon isorhamnetin treatment, and from 210 seconds onwards 
upon tamarixetin and quercetin treatment (Figure 5A-C, representative images shown in D). 
End point fluorescence values demonstrate a 41% ±5.9 inhibition of total thrombus 
formation upon isorhamnetin treatment, a 55%±12 reduction with tamarixetin, and 39% 8.9 
inhibition with quercetin. This trend toward an increased effect of tamarixetin is consistent 
with clot retraction data in that, in the presence of plasma proteins, a 4’ methyl group may 
confer higher inhibitory potency over a 3’ methyl group or a B ring catechol moiety. 
Isoquercetin inhibits thrombus formation in a murine model of arterial 
thrombosis 
Having displayed high inhibitory potency in vitro, the potential effect of quercetin on 
thrombosis in vivo was investigated. This was achieved using a laser injury model, in which 
thrombi are induced in cremaster muscle arterioles and observed via intravital microscopy. 
Isoquercetin was used in these experiments, as the route of administration was oral, and the 
3-glucoside moiety results in higher bioavailability and plasma quercetin concentrations 
compared to quercetin aglycone.28,29 Indeed, studies have demonstrated isorhamnetin and 
tamarixetin in plasma following isoquercetin administration, and after supplementation with 
other quercetin glucosides.12,30 A 48 hour dosing regimen was utilised, with morning and 
afternoon dosing, to mimic human supplemental consumption, and to investigate if repeated 
supplementation resulted in anti-thrombotic effects. Treatment with isoquercetin over 48h 
resulted in a 45%±11.9 reduction in maximum thrombus size (Figure 5E). Kinetically, upon 
injury, thrombi in vehicle-treated mice increased in size, reaching a peak at approximately 
160 seconds, after which thrombus size gradually declined. Upon isoquercetin administration, 
fluorescence levels initially rose similarly as platelets accumulated in the thrombus; however, 
growth was not sustained, with thrombi becoming unstable, platelets embolising and thrombi 
unable to grow to the same degree (see Suppl. Video 1 and 2)(Figure 5F). Representative 
images are shown in Figure 5G. Together, these data demonstrate the ability of an oral 
isoquercetin dose to inhibit thrombosis in vivo, suggesting the anti-platelet effects of 
quercetin’s metabolites are maintained in a whole, physiological system. 
 
Quercetin and its methylated metabolites enhance the anti-platelet effect of 
aspirin 
Aspirin use is associated with adverse bleeding events, and as such the lowering of doses may 
be desirable; one way to achieve this could be co-administration of flavonoid 
supplements.31,32 The effects of aspirin and flavonoids on collagen (5 g/mL) stimulated 
platelet aggregation, both individually and in combination, were therefore investigated. 
Aspirin alone inhibited aggregation of washed platelets at 10 M and above; combined 
flavonoid and aspirin treatment resulted in a significantly higher level of inhibition compared 
to aspirin alone at 2.5, 5 and 10µM isorhamnetin. A synergistic (more-than additive) 
enhancement of anti-platelet effect was observed at 2.5 and 5µM isorhamnetin; for example, 
treatment with 5µM isorhamnetin and 5µM aspirin resulted in a 59%±3.9 inhibition of 
aggregation, more than the sum of the effects of these individual concentrations (14%±1.4 
and 4%±2.3 inhibition, respectively)(p<0.05) (Figure 6A). In Figure 6, an “S” denotes a 
statistically significantly greater effect of dual treatment compared to the individual effects 
of flavonoids and aspirin added together (as opposed to simply an additive effect of including 
another inhibitor of platelet function). Similar results were observed for both 
tamarixetin/quercetin and aspirin dual treatment, with synergistic effects observed upon 
treatment with 2.5 and 5μM flavonoid (Figure 6C,E). The IC50 values for the inhibition of 
platelet aggregation by aspirin upon flavonoid co-administration highlight this interactive 
effect, with the IC50 value of 10.83μM (±0.45μM) for aspirin alone decreasing to 3.32μM (± 
1.08μM), 2.99μM (± 0.44μM) and 1.11μM (± 0.4 μM) upon addition of 2.5, 5 and 10μM 
quercetin, respectively (Figure 6F). Indeed, upon co-incubation of 10μM isorhamnetin and 
tamarixetin, half-maximal inhibition of aggregation was achieved at 0.8μM (±0.36μM) and 
0.52μM (± 0.1μM) aspirin respectively, lowering the IC50 of aspirin by over an order of 
magnitude (Figure 6B,D). Together, these data demonstrate the ability of isorhamnetin, 
tamarixetin and quercetin to reduce the IC50 value of aspirin in the inhibition of aggregation 
at concentrations as low as 2.5μM; plasma concentrations proven to be physiologically 
relevant.23,33 
 
The anti-platelet interaction between flavonoids and aspirin is maintained in a 
whole blood assay of platelet function 
Having established synergy between aspirin and the methylated metabolites of quercetin, we 
asked whether these interactions were maintained in a whole blood system, with the 
presence of interfering factors such as plasma proteins. This was tested using a Platelet 
Function Analyser (PFA)-100 instrument, first described by Kundu et al, which simulates 
primary haemostasis by drawing anticoagulated blood through an aperture cut into a 
membrane coated with collagen plus ADP (CADP) and providing a measurement of closure 
time (CT) of the aperture upon its occlusion.34 Treatment of whole blood with aspirin (25μM), 
isorhamnetin, tamarixetin or quercetin (10μM) individually did not significantly prolong the 
closure time. However, dual treatment with isorhamnetin and aspirin resulted in a significant 
prolongation of closure time, from 115 seconds (± 13.8) in vehicle-treated whole blood, to 
250s±50 upon isorhamnetin/aspirin combined treatment. This effect was more-than-additive 
when compared to individual treatment with isorhamnetin (CT 113s±9.8) and aspirin (CT 
115s±15.9) alone. This more-than-additive enhancement of effect was also seen upon dual 
treatment with tamarixetin/aspirin and quercetin/aspirin, with average closure times of 
253s±47 and 255s±30.3 respectively (tamarixetin alone, CT 121s±15.9; quercetin alone, CT 
100s±12.6)(Figure 6G). These results provide evidence for the maintenance of a more-than-
additive interaction between quercetin and its methylated metabolites and aspirin in the 
inhibition of platelet function in whole blood, highlighting a potential significance of this 
interaction in vivo. 
 
DISCUSSION 
It has been demonstrated in many studies that diets high in flavonoids are associated with 
reduced CVD risk, and a better understanding of the effects of dietary flavonoids on platelet 
function will help elucidate the mechanisms underlying this.6 Quercetin, one of the key dietary 
flavonoids worldwide, has been shown to dampen platelet function; however, on ingestion it 
is metabolised extensively, and significantly less attention has been focussed on these 
metabolites, the potential in vivo ‘effectors’. 13,35 In this study, the anti-thrombotic effects 
and underlying mechanisms of two common physiological methylated metabolites of 
quercetin – isorhamnetin and tamarixetin – were studied. 
We report that the methylated metabolites of quercetin, isorhamnetin and tamarixetin, 
potently inhibit platelet aggregation stimulated by collagen, with effects observed as low as 
1 M; a total plasma quercetin concentration achievable through both diet and supplemental 
means.23,33 As the primary, initial stimulus upon vessel injury, a strong inhibition of collagen-
stimulated platelet aggregation by the methylated metabolites of quercetin suggests early 
inhibitory effects, upon initial haemostatic challenge.21 Platelet aggregation stimulated via 
GPCR pathways, crucial for the positive feedback associated with platelet activation, were 
also affected. The ability of these flavonoids to inhibit this multitude of activatory pathways 
is likely through inhibition of kinases which are involved in both the initiation and propagation 
of platelet responses. Indeed, is has been shown that quercetin is able to inhibit the activity 
of many tyrosine and lipid kinases involved in platelet activation including Lyn, Fyn, Src, AKT, 
Syk and phosphoinositide 3-kinase (PI3K).13,36 The inhibition of activation through multiple 
GPCR pathways likely, at least in part, underlies the potent inhibition seen with these 
flavonoids. Secondary platelet activation through GPCR activating ligands is key for the 
positive feedback mechanisms that are necessary for a rapid and robust platelets response.2 
Dampened initial responses to collagen and subsequent inhibited GPCR signalling may be 
responsible for the high level of inhibition seen following exposure to quercetin metabolites, 
with platelets unable to activate fully due to inhibition of multiple key pathways. 
Consistent with an effect on platelet aggregation, isorhamnetin and tamarixetin potently 
inhibited granule secretion, with an effect on α-granule secretion at sub-micromolar 
concentrations. The mechanisms underlying the inhibition of granule secretion were not 
investigated; however, flavonoids have been shown to interfere with SNARE (soluble NSF  
attachment protein receptor) complex formation in mast cells, and quercetin has also 
demonstrated actin-binding properties, inhibiting its polymerization.37,38 In addition to this, 
inhibition of upstream activatory events (Ca2+ mobilization, receptor-proximal signalling 
events etc.) may suppress downstream granule secretion. 
A significant inhibition of integrin αIIbβ3 function was also demonstrated. The initial 
conformational change opening the integrin into a high affinity state that binds fibrinogen 
was strongly attenuated by quercetin, offering a mechanistic explanation for the observed 
reduction in aggregation. An increased potency of the aglycone over the methylated 
metabolites here may imply the presence of a potent un-investigated metabolite. Indeed, 
quercetin is metabolised extensively upon consumption; Hong et al identified 17 metabolites 
in human urine following consumption of cooked onions, and Lee et al identified 15 
metabolites in human plasma following enriched apple sauce consumption.39,40 It may also be 
that, in vivo, it is the combinations of metabolites that act together to potently inhibit platelet 
function. In addition, whilst the methylated metabolites may demonstrate increased effects 
at lower flavonoid concentrations, quercetin may have a larger maximal effect on integrin 
inside-out signalling; the reason for this is unclear but may be due to structural differences in 
the flavonoids. The adhesion and spreading of platelets on a fibrinogen-coated surface was 
also reduced upon flavonoid treatment, with an effect on integrin outside-in signalling 
confirmed with the observation of reduced clot retraction upon flavonoid treatment. Thus, 
quercetin and its methylated metabolites dampen integrin αIIbβ3 function downstream of 
GPVI and PAR1/4 activation. Such inhibition of clot retraction may be mediated via specific 
anti-platelet effects, such as disruption of actin cytoskeletal arrangement and recruitment of 
cytoskeletal-associated proteins such as myosin heavy chain to β3.41 In addition to this, Src 
family kinases (SFKs), specifically c-Src, have been shown to be crucial for integrin outside-in 
signalling, and quercetin potently inhibits SFKs including Fyn and Lyn.35,42 An inhibition of 
platelet activation induced by thrombin here agrees with the GPCR-stimulated aggregometry 
presented in this study, and offers further evidence for quercetin and its metabolites as 
inhibitors of the thrombin stimulated platelet activation pathway, even in the presence of 
plasma proteins. Quercetin has also exhibited anti-coagulant activities in numerous studies, 
including inhibitory effects on the enzymatic activity of thrombin and Factor Xa.43,44 Thus, the 
potential anti-coagulant effects of quercetin’s methylated metabolites must also be 
considered. Many flavonoids have been shown to inhibit intracellular enzymes key in signal 
transduction. For example, in platelets alone, it has been demonstrated that citrus flavonoids 
such as nobiletin inhibit PI3K-mediated signalling cascades, and genistein, luteolin, apigenin 
and quercetin itself inhibit total tyrosine phosphorylation and extracellular signal-regulated 
kinase (ERK)1/2 activation upon U46619 stimulation.18,45 As such, and due to the observed 
inhibition of early activation events such as granule secretion in this study, it was 
hypothesised that signalling events proximal to the GPVI receptor may be attenuated by the 
methylated metabolites of quercetin. Indeed, the phosphorylation of Syk and LAT, very early 
signalling events in platelets upon GPVI activation, were inhibited potently by isorhamnetin, 
tamarixetin and quercetin. This likely explains previous observations that collagen-stimulated 
phosphorylation of phospholipase Cγ2 is inhibited ex vivo after quercetin ingestion, as well 
as by quercetin and tamarixetin in vitro.12,49 Consistent with this, CRP-XL stimulated 
mobilisation of calcium was reduced upon flavonoid treatment. This alteration of early 
platelet signalling events likely explains the potent functional inhibition observed, with the 
mobilisation of calcium driving key processes such as integrin activation, TXA2 production and 
granule secretion.46 Indeed, inhibition early in the GPVI signalling pathway at the level of Syk 
and LAT (and subsequent calcium mobilization) is also likely to explain the inhibition of CRP-
XL/collagen-stimulated granule secretion, fibrinogen binding and platelet aggregation 
observed in this study, with these signalling molecules crucial to downstream platelet 
activation. The multitude of pathways and platelet functions inhibited by quercetin and its 
methylated metabolites in this study are displayed in Figure 7. In addition to this, a recent 
study by Doucet et al identified a hyperacetylated quercetin as a selective inhibitor of the 12-
lipoxygenase pathway, a pathway essential for platelet activation through the low affinity 
receptor for IgG, FcγRIIa; it may therefore be that the methylated metabolites of quercetin 
dampen platelet activation through this mechanism.48 
This study also demonstrates an anti-thrombotic effect of the methylated metabolites of 
quercetin, measured in vitro as an inhibition of thrombus formation under arterial flow 
conditions. A concentration of 10µM was used in this assay, corresponding to a physiologically 
achievable total plasma quercetin (plus metabolite) concentration upon 
supplementation.12,23 A trend toward increased potency of tamarixetin over quercetin and 
isorhamnetin was observed, similar to effects in clot retraction. These data therefore 
demonstrate the increased anti-platelet effect of a quercetin metabolite compared to the 
apparent a glycone, offering insight into how quercetin consumption could lead to anti-
platelet efficacy in vivo. The cause of increased potency is not established here, but there are 
several potential explanations for this. It has been demonstrated that tamarixetin binds 
collagen and fibrinogen with a much higher affinity than quercetin; this could interfere with 
platelet:ligand binding in this assay, which relies on a collagen-coated surface for platelet 
activaton.49  A study by Dufour et al observed a 2-3X reduction in binding constants to bovine 
serum albumin upon methylation of quercetin at the 4’ hydroxyl residue; reduced binding to 
albumin may therefore result in greater levels of available metabolite and therefore an 
apparent increase in efficacy.50 It is hypothesised that the enhanced potency of tamarixetin is 
not, therefore, due to increased anti-platelet activit per se, but rather altered 
bioavailability/platelet-ligand binding. 
An anti-thrombotic effect was demonstrated in vivo upon oral supplementation in mice with 
200mg/kg isoquercetin over a 48-hour period. Thrombi were unstable and prone to 
embolization upon isoquercetin treatment; this may be due to impaired integrin αIIbβ3 
outside-in signalling, which has a proven role in thrombus stabilization and is shown in the 
present study to be attenuated by quercetin and its methylated metabolites.51 A recent study 
by Feng et al reported a similar phenotype in a knock-in mouse with impaired β3 
phosphorylation which displayed delayed vessel occlusion and unstable thrombi upon 
injury.52 Isoquercetin itself is unlikely to be identified in plasma after oral supplementation 
due to glycoside hydrolysis by enzymes such as enterocyte lactin-phlorizin hydrolase (LPH) 
and -glucosidases.53 Indeed, upon oral isoquercetin administration, Paulke et al identified 
isorhamnetin/tamarixetin in rat plasma.29 The identification of the active metabolite(s) in the 
in vivo assay presented in this study, and their pharmacokinetic parameters, is therefore a 
primary goal of further research. A previous study from Hubbard et al also identified 
isorhamnetin and tamarixetin in human plasma upon ingestion of quercetin-4’-O- -D-
glucoside, a glucosidated form of quercetin similar to isoquercetin.12 Isorhamnetin and 
tamarixetin displayed similar pharmacokinetic properties to quercetin, accumulating with a 
tmax between 30-45 minutes.12 Thus, with repeated dosing through diet or supplementation, 
it may be possible that these metabolites (and other as yet unidentified metabolites) may 
accumulate in plasma or within platelets and exert their anti-platelet activities as established 
in this study. Indeed, a study evaluating metabolite identification and pharmacokinetics post-
isoquercetin supplementation in humans is another goal of further research. Nevertheless, 
these data demonstrate both the oral bioavailability of isoquercetin and a protective effect 
against thrombosis. 
Aspirin is one of the most widely used anti-platelet agents worldwide.54 Its use is associated 
with adverse events such as gastric bleeding, and whilst studies have shown that decreasing 
aspirin doses reduces adverse event numbers without a reduction in anti-platelet efficacy, 
even low dose aspirin treatment is associated with an increased bleeding risk.31,32 As such, the 
pharmacological implications of the effects of the methylated metabolites of quercetin with 
respect to the anti-platelet effects of aspirin are worthy of consideration. A preliminary 
investigation in this study demonstrated that isorhamnetin, tamarixetin and quercetin all 
increased the anti-aggregatory effects of aspirin in a synergistic i.e. more-than-additive 
manner, lowering IC50 values by over an order of magnitude at higher concentrations. In 
addition to this, isorhamnetin, tamarixetin and quercetin enhanced the effect of aspirin in a 
whole blood assay of platelet function (PFA-100) more-than-additively. The mechanism 
underlying this interaction is not established here but could be for several reasons. Several 
studies have demonstrated the ability of quercetin to directly inhibit COX-1 activity; indeed, 
Al-Fayez et al established an IC50 of ~5µM on purified COX-1.56 In vivo metabolites of 
quercetin may therefore be able to inhibit COX-1 at physiologically relevant levels. This holds 
clear implications for thromboxane synthesis. Indeed, Guerrero et al showed that quercetin 
can inhibit the production of thromboxane B2 downstream of collagen and arachidonic acid 
stimulation of platelets. Co-administration with flavonoids may therefore allow further 
lowering of aspirin doses to be achieved. It must also be considered that such interactions 
between the effects of dietary flavonoids and aspirin may act as interfering factors in the use 
of anti-platelet agents, potentially explaining variability in response to such agents. Further 
research is needed to elucidate the potentially helpful (enhanced antithrombotic effect) or 
harmful (compromised haemostasis) effects of flavonoid:anti-platelet medication 
interactions in vivo. 
Our study has demonstrated that isorhamnetin and tamarixetin inhibit platelet function and 
thrombus formation through effects on early activatory processes including calcium 
mobilisation, granule secretion and integrin activation. These metabolites, as well as 
quercetin aglycone, synergise with aspirin to enhance anti-platelet efficacy. Combined with 
the in vivo anti-thrombotic effect of isoquercetin demonstrated here, this may offer insight 
into new cardiovascular disease treatment avenues, and offer evidence into the link between 
flavonoid intake and reduced CVD risk.  
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Figure 1: Isorhamnetin and tamarixetin, the methylated metabolites of quercetin, 
inhibit collagen-stimulated platelet aggregation. Washed human platelets (2 x 108 
cells/mL) were incubated with isorhamnetin (A/B), tamarixetin (C/D), quercetin (E/F) or 
vehicle (DMSO, 0.2% v/v) for 5 minutes (with 10 seconds stirring to mix) prior to addition of 
collagen (5μg/mL). Aggregation was measured for 5 minutes at 37oC under constant stirring 
(1200rpm) conditions in a Chrono-Log optical platelet aggregometer. (A,C,E) Representative 
traces from aggregation assays. (B,D,F) Four parameter nonlinear regression curves, used to 
estimate the IC50 of isorhamnetin, tamarixetin and quercetin. N=3, data represent mean ± 
SEM. I, isorhamnetin; T, tamarixetin; Q, quercetin 
 
Figure 2: Isorhamnetin, tamarixetin and quercetin inhibit platelet granule 
secretion. Washed platelets (4 x 108 cells/mL) were treated with flavonoid or vehicle control 
(DMSO, 0.25% v/v) for 5 minutes, with 50 L Chronolume luminescent substrate added in 2 
minutes prior to stimulation. Collagen (5 g/mL) was added to stimulate platelets and ATP 
secretion was monitored for 180 seconds under stirring conditions (1200rpm) at 37oC. (A,E,I) 
Representative traces showing increase in luminescence upon ATP secretion and inhibition 
by flavonoids. (B,F,J) ATP secretion as a percentage of the amount secreted in the absence of 
isorhamnetin, tamarixetin or quercetin (vehicle). Washed platelets (2 x 108 cells/mL) were 
incubated with isorhamnetin (C/D), tamarixetin (G/H), quercetin (K/L) or vehicle control  
(DMSO, 0.25% v/v) for 5 minutes, after which PE/Cy5 anti-human CD62P antibody was added 
to sample prior to stimulation. Samples were then stimulated with CRP-XL (1μg/mL) for 20 
minutes, after which they were fixed in 0.2% paraformaldehyde. P-Selectin exposure on the 
cell surface was then measured by flow cytometry and data normalized to the level of P-
Selectin exposure in the absence of flavonoid (vehicle) (D,H,L). Four parameter nonlinear 
regression curves were utilised to estimate the IC50 of isorhamnetin (C), tamarixetin (G) and 
quercetin (K). N=3, data represent mean ± SEM. *p<0.05, **p<0.005, ****p<0.0001 
compared to vehicle control, analysed by one-way ANOVA with post-hoc Dunnett’s test. I, 
isorhamnetin; T, tamarixetin; Q, quercetin. 
 
Figure 3: Integrin αIIbβ3 affinity and function is altered by quercetin’s 
methylated metabolites. Washed platelets (2 x 108 cells/mL) were incubated with 
isorhamnetin (A), tamarixetin (B), quercetin (C) or vehicle control (DMSO, 0.25% v/v), 
stimulated with CRP-XL (1μg/mL), and fibrinogen binding measured by flow cytometry. Data 
normalized to the level of fibrinogen binding in the absence of flavonoid (vehicle). Washed 
platelets (2 x 108 cells/mL) were incubated with isorhamnetin (E), tamarixetin (F), quercetin 
(G) or vehicle control (DMSO 0.33% v/v) for 5 minutes, then allowed to spread on fibrinogen 
(100μg/mL) coated coverslips for 45 minutes at 37oC. Cells were stained with Alexa fluor 488 
phalloidin and visualised using a Nikon A1-R confocal microscope. Data represent percentage 
of platelets in each stage of spreading (E,F,G), mean ± SEM, with representative images in (D). 
PRP was incubated with isorhamnetin (H), tamarixetin (I), quercetin (J) or vehicle control 
(DMSO, 0.2% v/v) for 60 minutes at 30oC, after which thrombin (1U/mL) was added to 
stimulate clot formation. The assay was terminated at 120 minutes when vehicle-treated clots 
had retracted fully, with representative images shown as well as clot weight at 120 mins. N=4, 
data represent mean ± SEM. *p<0.05, **p<0.005, ***p<0.001, ****p<0.0001 compared to 
vehicle control, analysed by one-way ANOVA with post-hoc Dunnett’s test. I, Isorhamnetin; T, 
tamarixetin; Q, quercetin. 
 
Figure 4: Isorhamnetin, tamarixetin and quercetin inhibit calcium mobilisation 
and signalling proximal to GPVI. Fura-2 loaded washed platelets (4 x 108 cells/mL) were 
incubated with isorhamnetin (A,B), tamarixetin (C,D), quercetin (E,F) or vehicle control 
(DMSO, 0.2% v/v) for 5 minutes at 37oC prior to stimulation with CRP-XL (1μg/mL). 
Fluorescence (excitation 340 and 380nm, emission 510nm) was recorded for 5 minutes using 
a NOVOstar plate reader, and [Ca2+]i was estimated using the equation described in the 
Methods (A,C,E). Peak [Ca2+]i was taken as the maximum value reached in the sample over 
the 5 minute period, and was normalised to peak calcium levels in the absence of flavonoid 
(vehicle) (B,D,F). N=4, data in B,D,F represent mean ± SEM, analysed by one-way ANOVA with 
post-hoc Dunnett’s test. *p<0.05, **p<0.005, ***p<0.001, ****p<0.0001 compared to 
vehicle control. Washed human platelets (4 x 108 cells/mL) were incubated with isorhamnetin 
(I/L), tamarixetin (J/M), quercetin (K/N) or vehicle control (DMSO, 0.4% v/v) for 5 minutes at 
37oC prior to addition of CRP-XL (1μg/mL). Aggregation was allowed to occur for defined time 
points, after which samples were immediately lysed in 6X reducing sample buffer. Proteins 
were separated by SDS-PAGE and immunoblotted for phosphorylated Syk (Y525+526) and LAT 
(Y200). Levels of fluorescence of individual bands were normalised to loading controls 
(integrin β3), with representative blots shown in G/H. N=3, data represent mean ± SEM. 
*p<0.05, **p<0.005, ****p<0.0001 compared to vehicle control at corresponding time 
points, analysed by two-way ANOVA with post-hoc Bonferroni correction. I, isorhamnetin; T, 
tamarixetin; Q, quercetin; Syk, Spleen tyrosine kinase; LAT, Linker for activation of T cells; SDS-
PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis. 
 
Figure 5: Isorhamnetin, tamarixetin and quercetin display anti-thrombotic 
actions in vitro, and isoquercetin inhibits thrombosis in vivo. DiOC6-labelled whole 
blood was incubated with isorhamnetin (A), tamarixetin (B), quercetin (C) (10μM) or vehicle 
control (DMSO, 0.2% v/v) prior to perfusion through collagen-coated Vena8 biochip channels 
at a shear rate of 20dyn/cm2, with images captured every second for 600s. Mean fluorescence 
intensity was normalised to the level in the absence of flavonoid (vehicle) and was calculated 
using NIS Elements software (A-C), and representative images at the assay endpoint are 
shown in (D). C57BL/6 mice were dosed twice per day (9am and 5pm) with isoquercetin 
(200mg/kg) or vehicle control (distilled water) by gavage for 48 hours prior to the experiment, 
with one final dose administered on the morning of the experiment. Mice were 
anaesthetised, platelets were labelled with DyLight 649 anti-GPIbα antibody, and laser injury 
of a cremaster muscle arteriole wall was performed with a Micropoint ablation laser unit. 
Thrombus formation was observed using an Olympus BX61W1 microscope, with images 
analysed to calculate fluorescence intensity of thrombi using Slidebook software (version 6). 
Maximum fluorescence of samples reached over the assay (E). Median integrated 
fluorescence values from all thrombi are shown in (F). Representative images from 
experiments at different time points are shown in (G); scale bars in bottom left of the images 
represent 10μm. For in vitro data; N=3, data represent mean ± SEM. *p<0.05, **p<0.005, 
***p<0.001, ****p<0.0001 compared to vehicle control, analysed by two-way ANOVA with 
post-hoc Bonferroni correction. For in vivo data; N=4, with multiple thrombi per mouse. 
*p<0.05 compared to vehicle control, data in (E) represent mean ± SEM, analysed by unpaired 
t-test. 
 
Figure 6: Isorhamnetin, tamarixetin and quercetin synergise with aspirin to 
enhance antiplatelet effects. Washed platelets (2 x 108 cells/mL) were incubated in a 96 
well plate with aspirin ± isorhamnetin (A/B), tamarixetin (C/D), quercetin (E/F) (5μM flavonoid 
shown as example) or vehicle control (0.25% ethanol + 0.5% DMSO, v/v), and aggregation 
stimulated by collagen (5μg/mL). Data represent percentage aggregation normalised to levels 
of aggregation in the absence of flavonoid (vehicle)(A,C,E). (B,D,F) IC50 values for aspirin upon 
addition of flavonoid. N=3, data represent mean ± SEM. *p<0.05, **p<0.005, ***p<0.001, 
****p<0.0001. Blue stars indicate a significant effect of aspirin compared to vehicle control, 
analysed by 1-way ANOVA. Black stars indicate a significant effect of flavonoid plus aspirin 
compared to aspirin alone, analysed by 2-way ANOVA. “S” indicates an enhanced effect of 
dual treatment compared to the combined effects of individual flavonoid and aspirin 
concentrations (p<0.05), analysed by paired t-test. Whole blood was incubated with 
quercetin ± aspirin, tamarixetin ± aspirin, isorhamnetin ± aspirin, aspirin alone or vehicle 
control (0.1% DMSO + 0.1% ethanol) for 30 minutes at 30oC. Whole blood was loaded into the 
reservoir of CADP cartridges and samples were run through the PFA-100, with closure time 
(s) shown in (G). N=3, data represent mean ± SEM. Stars represent a significant prolongation 
of closure time compared to vehicle control. *p<0.05, analysed by one-way ANOVA. “S” 
represents a synergistic effect as described above. I, isorhamnetin; T, tamarixetin; Q, 
quercetin; ASA, acetylsalicylic acid (aspirin); CADP, collagen plus adenosine diphosphate. 
 
Figure 7: A model demonstrating the multiple platelet activation pathways 
inhibited by the methylated metabolites of quercetin. Isorhamnetin, tamarixetin and 
quercetin inhibit multiple aspects of the GPVI activation pathway, including Syk and LAT 
phosphorylation, alpha and dense granule secretion, calcium mobilization, integrin αIIbβ3 
inside-out signalling and, ultimately, aggregation (indicated by the red text). In addition, this 
study demonstrates an inhibition of platelet aggregation downstream of ADP, thrombin and 
U46619 stimulation. This multitude of inhibitory effects culminates in the potent inhibition 
observed upon treatment with isorhamnetin, tamarixetin or quercetin, and results in 
attenuated thrombus formation. ADP, adenosine phosphate; GPCR, G-Protein coupled 
receptor; GPVI, Glycoprotein VI; IP3, inositol 1,4,5-trisphosphate; I, Isorhammetin; LAT, Linker 
for Activation of T Cells; PLC 2, Phospholipase C 2; PIP2, Phosphatidylinositol 4,5- 
bisphosphate; Q, Quercetin; Syk, Spleen Tyrosine Kinase; T, Tamarixetin; TXA2, Thromboxane 
A2. 
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Supplementary Figure S1: The structures of quercetin, tamarixetin and 
isorhamnetin. The structures of the compounds investigated; quercetin (A), tamarixetin (B), 
and isorhamnetin (C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S2: Quercetin and its methylated metabolites inhibit 
platelet aggregation evoked by multiple concentrations of collagen. Washed 
platelets (2 x 108 cells/mL) were incubated in a 96 well plate with isorhamnetin (A), 
tamarixetin (B), quercetin (C) or vehicle control (DMSO, 0.2% v/v) for 5 minutes, with 
aggregation subsequently measured via plate-based aggregometry. Data represent 
percentage aggregation with each agonist concentration normalised to levels of aggregation 
in the absence of flavonoid  (vehicle). N=4, data represent mean ± SEM. Data analysed by one-
way ANOVA with post-hoc Dunnett’s test, coloured stars refer to statistical significance 
compared to vehicle control against the agonist indicated by the same colour line in the 
legend. *p<0.05, **p<0.005, ***p<0.001, ****p<0.0001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S3: Isorhamnetin, tamarixetin and quercetin inhibit 
platelet aggregation stimulated through G-protein coupled receptors. Washed 
platelets (2 x 108 cells/mL) were incubated in a 96 well plate with isorhamnetin (A,D,G), 
tamarixetin (B,E,H), quercetin (C,F,I) or vehicle control (DMSO, 0.2% v/v) for 5 minutes, with 
aggregation subsequently measured via plate-based aggregometry. Data represent 
percentage aggregation with each agonist concentration normalised to levels of aggregation 
in the absence of flavonoid (vehicle). N=4, data represent mean ± SEM. Data analysed by one-
way ANOVA with post-hoc Dunnett’s test, coloured stars refer to statistical significance 
copared to vehicle control against the agonist indicated by the same colour line in the legend. 
*p<0.05, **p<0.005, ***p<0.001, ****p<0.0001. ADP, adenosine diphosphate. 
Supplementary Figure S4: Isorhamnetin, tamarixetin and quercetin inhibit 
platelet aggregation in PRP. Platelet rich plasma was incubated in a 96-well plate with 
isorhamnetin (A), tamarixetin (B), quercetin (C) or vehicle control (DMSO, 0.2% v/v) for 30 
minutes at 37oC prior to stimulation with collagen (5 g/mL). Data represent percentage 
aggregation normalised to levels of aggregation in the absence of flavonoid (vehicle). N=4, 
data represent mean ± SEM. *p<0.05, **p<0.005, ***p<0.001, ****p<0.0001, data analysed 
by one-way ANOVA with post-hoc Dunnett’s test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Video 1: Example of thrombus formation in vivo in vehicle-treated mice. 
Supplementary Video 2: Example of thrombus formation in vivo in isoquercetin-treated 
mice. 
 
What is known about this topic? 
 Diets high in flavonoid intake have been linked to reduced CVD risk, thought at least in part 
to be due to anti-platelet effects 
 Quercetin, one of the main dietary flavonoids, has demonstrated anti-aggregatory effects 
in previous in vitro studies, but is extensively metabolised upon consumption 
 Prophylactic aspirin use is associated with adverse bleeding events, and as such lowering 
aspirin doses may be desirable 
 
What does this paper add? 
 Two physiologically relevant methylated metabolites of quercetin, tamarixetin and 
isorhamnetin, display potent anti-platelet effects through inhibition of granule secretion, 
integrin IIb 3 function, and calcium mobilisation, and these metabolites possess anti-
thrombotic effects  
 An in vivo anti-thrombotic effect of isoquercetin, a main dietary form of quercetin, is 
established, providing insight into how flavonoid consumption may lead to antithrombotic 
effects and reduced CVD risk 
 Quercetin, tamarixetin and isorhamnetin enhance the anti-platelet effects of aspirin in a 
synergistic, more-than-additive manner, offering a potential avenue to further reducing 
aspirin doses 
